Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway. - Wikidata - awgldk - TriplyDB

Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.

Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.

http://www.wikidata.org/entity/Q33674106

about

A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer miR‑590‑5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression

P2860

Q36407203-4F395B9E-38E8-446C-84DA-C652D9F6ACDC Q58796939-3CED34DA-2B5E-4181-B0C8-45B551D35817

P2860

Circulating microRNA-194 regulates human melanoma cells via PI3K/AKT/FoxO3a and p53/p21 signaling pathway.

http://www.wikidata.org/entity/Q33674106

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@ast

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@en

type

label

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@ast

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@en

prefLabel

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@ast

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@en

P1433

Q33674106-8B1DEDB7-14D3-4825-9853-7B5EE85AD5C6

P1476

Q33674106-7F0E4838-982F-45C5-A869-F4C2E8E71B85

P2093

Q33674106-38F36073-0AA8-4999-B1C4-D24AF9873222

Q33674106-447BBAB6-F65F-4A57-9762-3062A02AF3FE

Q33674106-7BDCF6C8-BFD2-40B2-B083-60A001A89250

Q33674106-AC7F9FF2-06BB-42A0-9408-CE8E82423DC2

Q33674106-B0CB2D04-9EEC-43C6-9EC0-C1E5C912D88F

Q33674106-CD9B5EAA-3C59-49BE-B4F3-1197C77453FE

P2860

Q33674106-11D1C706-4F57-40A8-B55F-5FC68E9DA599

Q33674106-1BBE1731-E2A1-4F4F-BE8D-EF84BAE7C53B

Q33674106-1F40A35A-DCC7-4A5C-9B8F-5490A58F62C3

Q33674106-260737EE-1024-4615-81E5-99F2AF26F082

Q33674106-298E2C22-427F-4E0C-8244-3088009C5164

Q33674106-2CE1734E-B6B4-4B7E-892E-8EF3D5FBC690

Q33674106-32A4F6FE-B88E-4065-AC39-4BBCC1069143

Q33674106-452B4E9B-321A-4E81-BA1B-D8B645327756

Q33674106-49A22AFA-D251-4633-A668-C8E538979CC1

Q33674106-4A9C9943-8518-4948-82EC-DE65EFD8199C

P304

Q33674106-8AAC0DC9-0E6B-45E1-BCDC-7C0158DCE333

P31

Q33674106-AC58BBDC-A170-476F-BB9E-2BCBF7F96A45

P356

Q33674106-754CF2B4-710E-49B3-AE05-369B0729F80D

P433

Q33674106-BA6904E0-305E-4810-A89E-6335F188AF9A

P478

Q33674106-A2B3B226-1820-4BD3-B26A-8F624D5D59C0

P577

Q33674106-2A087D12-EF50-4007-8665-2F80D3A301AC

P698

Q33674106-E8E34771-C66E-4160-BD1C-C40369B153FE

P921

Q33674106-80299A75-9C2E-429B-91B7-EB5F30D00874

P932

Q33674106-A4806E6F-5D27-4493-9BF0-0D164287F82F

P356

P1433

Oncology Reports

P1476

Circulating microRNA-194 regul ...... and p53/p21 signaling pathway.

@en

P2093

Ang Zeng

http://www.w3.org/2001/XMLSchema#string

Fei Long

http://www.w3.org/2001/XMLSchema#string

Ming Bai

http://www.w3.org/2001/XMLSchema#string

Mingzi Zhang

http://www.w3.org/2001/XMLSchema#string

Nanze Yu

http://www.w3.org/2001/XMLSchema#string

Ru Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer

Microarray and ChIP-seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cells

A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.

MicroRNA-194 is a target of transcription factor 1 (Tcf1, HNF1α) in adult liver and controls expression of frizzled-6.

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers

Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensi

Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations.

P304

2702-2710

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OR.2017.5537

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28358423

http://www.w3.org/2001/XMLSchema#string

P921

P932

5428795

http://www.w3.org/2001/XMLSchema#string